Status:
COMPLETED
Effect of Probiotics on the Fecal Resistome During Helicobacter Pylori Eradication Therapy
Lead Sponsor:
Universidad San Francisco de Quito
Collaborating Sponsors:
Universidad Tecnológica Equinoccial
Biocodex
Conditions:
Gut Resistome
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
Eradication therapy against Helicobacter pylori (Hp) carries adverse effects, such as altering the intestinal microbiota's structure and function and selecting commensals and pathogens resistant to an...
Detailed Description
Antibiotic use is one of the most common therapeutic strategies of modern medicine. Together with the significant beneficial effects of antibiotic use, side effects accompany the use of these drugs, i...
Eligibility Criteria
Inclusion
- Patients with typical dyspepsia symptoms from whom an upper gastrointestinal endoscopy with biopsies was done for histopathological examination.
Exclusion
- Pregnancy or lactation.
- Subjects diagnosed with another gastrointestinal disease such as inflammatory bowel disease and malabsorption syndromes.
- Subjects taking or are planning to take pre- pro- or symbiotic.
- Subjects that have received antibiotics in the last month for any reason.
- Subjects who have received corticosteroids chronically for any reason; have received medication to inhibit nutrient absorption; use of NSAID during the last month that cannot stop the treatment.
Key Trial Info
Start Date :
April 7 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 9 2017
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04786938
Start Date
April 7 2016
End Date
June 9 2017
Last Update
October 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.